New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear.
暂无分享,去创建一个
James M Wright | Sylvie Chabaud | François Gueyffier | Jean-Pierre Boissel | Alain Leizorovicz | Michel Cucherat | Patrice Nony | F. Gueyffier | J. Boissel | M. Cucherat | A. Leizorovicz | P. Nony | S. Chabaud | M. Lièvre | Michel Lièvre | J. Wright
[1] D L Sackett,et al. An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.
[2] Douglas G Altman,et al. The relation between treatment benefit and underlying risk in meta-analysis , 1996, BMJ.
[3] J. Collet,et al. An Effect Model for the Assessment of Drug Benefit: Example of Antiarrhythmic Drugs in Postmyocardial Infarction Patients , 1993, Journal of cardiovascular pharmacology.
[4] Sylvie Chabaud,et al. Clinical Trial Simulation Using Therapeutic Effect Modeling: Application to Ivabradine Efficacy in Patients with Angina Pectoris , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[5] T Stijnen,et al. Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. , 2000, Statistics in medicine.
[6] D E Grobbee,et al. Does drug treatment improve survival? Reconciling the trials in mild‐to-moderate hypertension , 1995, Journal of hypertension.
[7] François Gueyffier,et al. Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems , 2003, Clinical chemistry and laboratory medicine.
[8] S. Senn. Individual response to treatment: is it a valid assumption? , 2004, BMJ : British Medical Journal.
[9] I. Wiklund,et al. Physical inactivity as a risk factor for primary and secondary coronary events in Göteborg, Sweden. , 1988, European heart journal.
[10] L. Stewart,et al. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.
[11] M. McIntosh,et al. The population risk as an explanatory variable in research synthesis of clinical trials. , 1996, Statistics in medicine.
[12] J. Boissel,et al. Revisiting the effect compartment through timing errors in drug administration. , 1998, Trends in pharmacological sciences.
[13] J. Boissel,et al. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. , 1990, The American journal of cardiology.
[15] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.
[16] S. Yusuf,et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .
[17] J. Boissel. Individualizing aspirin therapy for prevention of cardiovascular events. , 1998, JAMA.
[18] Les M Irwig,et al. An evidence based approach to individualising treatment , 1995, BMJ.
[19] K A L'Abbé,et al. Meta-analysis in clinical research. , 1987, Annals of internal medicine.
[20] L. Aarons,et al. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] Karla Kerlikowske,et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials , 1999, The Lancet.
[22] L Aarons,et al. A pharmacokinetic simulation model for ivabradine in healthy volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.